Literature DB >> 19250061

Common genetic variation in DDAH2 is associated with intracerebral haemorrhage in a Chinese population: a multi-centre case-control study in China.

Yongyi Bai1, Jingzhou Chen, Kai Sun, Ying Xin, Junhao Liu, Rutai Hui.   

Abstract

ADMA (asymmetric omega-NG,NG-dimethylarginine), an endogenous inhibitor of NOS (NO synthase), has been shown to be an independent predictor of cerebrovascular disorders. DDAH2 (dimethylarginine dimethylaminohydrolase 2) promotes the metabolism of ADMA and plays a key role in the regulation of the acute inflammatory response. We hypothesized that genetic variation in DDAH2 might alter the susceptibility to ICH (intracerebral haemorrhage). The hypothesis was tested in two independent case-control studies. We used a haplotype-tagging SNP (single nucleotide polymorphism) approach to identify tag SNPs in DDAH2. The SNPs were genotyped in 1603 stroke patients and 1525 control subjects. The study was replicated in another independent case-control study including 322 stroke patients and 891 control subjects. A promoter variant -449C/G (rs805305) in DDAH2 was identified and found to be in complete linkage disequilibrium with the only tag SNP (rs707916) in the region containing DDAH2. Genotype analyses were conducted for both dominant and additive models. The C allele of the -449 locus resulted in a significantly reduced risk of ICH {dominant model: OR (odds ratio), 0.51 [95% CI (confidence interval), 0.38-0.68], P=6.60x10-6; additive model: OR, 0.64 (95% CI, 0.52-0.80), P=5.21x10-5} than the wild-type genotype. No association was observed between the DDAH2 variant and atherothrombotic stroke. The findings were replicated in the second independent population. In conclusion, our results suggest that the DDAH2 common variant may play a protective role in the development of ICH, implicating that the DDAH2/ADMA pathway may act as a critical regulator of cerebral small-vessel disorders.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19250061     DOI: 10.1042/CS20090005

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  6 in total

Review 1.  The therapeutic potential of targeting endogenous inhibitors of nitric oxide synthesis.

Authors:  James Leiper; Manasi Nandi
Journal:  Nat Rev Drug Discov       Date:  2011-04       Impact factor: 84.694

2.  Pilot study of the association of the DDAH2 -449G polymorphism with asymmetric dimethylarginine and hemodynamic shock in pediatric sepsis.

Authors:  Scott L Weiss; Min Yu; Lawrence Jennings; Shannon Haymond; Gang Zhang; Mark S Wainwright
Journal:  PLoS One       Date:  2012-03-12       Impact factor: 3.240

3.  A functional variant in promoter region of platelet-derived growth factor-D is probably associated with intracerebral hemorrhage.

Authors:  Yongyi Bai; Jingzhou Chen; Kai Sun; Yibo Wang; Rutai Hui
Journal:  J Neuroinflammation       Date:  2012-01-30       Impact factor: 8.322

4.  A functional variant of the dimethylarginine dimethylaminohydrolase-2 gene is associated with insulin sensitivity.

Authors:  Francesco Andreozzi; Ivan Presta; Gaia Chiara Mannino; Daniela Scarpelli; Sara Di Silvestre; Natalia Di Pietro; Elena Succurro; Angela Sciacqua; Assunta Pandolfi; Agostino Consoli; Marta Letizia Hribal; Francesco Perticone; Giorgio Sesti
Journal:  PLoS One       Date:  2012-04-27       Impact factor: 3.240

5.  Differentially Expressed Genes and Their Clinical Significance in Ischaemic Stroke: An In-Silico Study.

Authors:  Sandeep Appunni; Muni Rubens; Venkataraghavan Ramamoorthy; Hina Sharma; Anjani Kumar Singh; Vishnu Swarup; Himanshu Narayan Singh
Journal:  Malays J Med Sci       Date:  2020-12-29

6.  Dimethylarginine Dimethylaminohydrolase 2 (DDAH 2) Gene Polymorphism, Asymmetric Dimethylarginine (ADMA) Concentrations, and Risk of Coronary Artery Disease: A Case-Control Study.

Authors:  Chao Xuan; Long-Qiang Xu; Qing-Wu Tian; Hui Li; Qing Wang; Guo-Wei He; Li-Min Lun
Journal:  Sci Rep       Date:  2016-09-28       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.